TIDES Europe: Oligonucleotide and Peptide Therapeutics is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Macarena Hernández-Jiménez
Chief Scientific Officer at AptaTargets S.L.

Profile

PhD in Biomedicine with more than 10 years of experience in neurosciences and pharmacology in cerebrovascular diseases, in addition to 6 years of experience in the Stroke National Investigation consortium (INVICTUS).


Ms. Hernández-Jiménez has worked at the Ramón y Cajal Hospital (Madrid, Spain) and collaborated with 12 hospitals in the investigation of large translational preclinical studies in stroke. PhD and postdoctoral positions in topics related to cerebral hypoxia-ischemia in the hospital setting (Ramón y Cajal Hospital and La Paz Hospital) and in cerebral ischemia and pharmacology at the Complutense University (Neurovascular Research Unit). Currently, CSO of AptaTargets focused in preclinical studies and clinical trials required to develop a new aptameric therapy for the treatment of stroke patients.

Macarena Hernández-Jiménez's Network

Agenda Sessions

  • ApTOLL, A New Therapeutic Approach for the Treatment of Ischemic Stroke

    , 09:00